Skip to main content

Table 4 Abnormal movement assessments and side effects of RLAI* and FGAI therapy

From: Risperidone long-acting injection in Schizophrenia Spectrum Illnesses compared to first generation depot antipsychotics in an outpatient setting in Canada

Treatment outcome

RLAI

FGAI

P value

Abnormal movement

 

  AIMS score completed (n (%))

36 (51.4)

61 (59.8)

0.28

  Mean AIMS score

1.83

3.25

0.25

  Proportion of patients with TD (n (%))

1 (1.4)

5 (4.9)

0.40

 SAS score completed

33 (47.1)

54 (52.9)

0.45

  Mean SAS score

2.82

4.85

0.28

  Proportion of patients with EPS

12 (17.0)

54 (52.9)

<0.001

Side effects of therapy (n (%))

 

 Patients reporting side effects

7 (10.0)

17 (16.7)

0.21

  EPS

1 (14.3)

3 (17.6)

 

  Akathesia

1 (14.3)

2 (11.8)

 

  Weight gain

2 (28.6)

2 (11.8)

 

  Tremor

0 (0)

4 (23.5)

 

  Galactorrhea

1 (14.3)

0 (0)

 

  Other

2 (28.6)

6 (35.5)

 
  1. * Abbreviations are: RLAI Risperidone long-acting injection, FGAI First generation antipsychotic injection, AIMS Abnormal Involuntary Movement Scale, TD tardive dyskinesia, SAS Simpson Angus Scale, EPS extrapyramidal symptoms.
  2. Other includes injection site pain, dizziness, fatigue, TD (FGAI) and mental impairment (RLAI).